{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:50:58Z","timestamp":1768722658602,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T00:00:00Z","timestamp":1347321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T00:00:00Z","timestamp":1347321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10637-012-9877-8","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T03:23:12Z","timestamp":1347247392000},"page":"473-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin"],"prefix":"10.1007","volume":"31","author":[{"given":"Tetsuya","family":"Tanimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Tsubokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinichi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Pietrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,11]]},"reference":[{"issue":"17","key":"9877_CR1","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/jnci\/djq350","volume":"102","author":"M Goozner","year":"2010","unstructured":"Goozner M (2010) FDA increases focus on postmarketing studies. J Natl Cancer Inst 102(17):1302\u20131304","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9877_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1056\/NEJMp1005843","volume":"363","author":"RC Young","year":"2010","unstructured":"Young RC (2010) Cancer clinical trials\u2014a chronic but curable crisis. N Engl J Med 363(4):306\u2013309","journal-title":"N Engl J Med"},{"issue":"26","key":"9877_CR3","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1200\/JCO.2008.21.1961","volume":"27","author":"EA Richey","year":"2009","unstructured":"Richey EA, Lyons EA, Nebeker JR et al (2009) Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 27(26):4398\u20134405","journal-title":"J Clin Oncol"},{"issue":"6","key":"9877_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/clpt.2010.207","volume":"88","author":"WP Boon","year":"2010","unstructured":"Boon WP, Moors EH, Meijer A, Schellekens H (2010) Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther 88(6):848\u2013853","journal-title":"Clin Pharmacol Ther"},{"issue":"9798","key":"9877_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S0140-6736(11)61098-2","volume":"378","author":"K Shibuya","year":"2011","unstructured":"Shibuya K, Hashimoto H, Ikegami N et al (2011) Future of Japan\u2019s system of good health at low cost with equity: beyond universal coverage. Lancet 378(9798):1265\u20131273","journal-title":"Lancet"},{"issue":"26","key":"9877_CR6","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID (2012) Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119(26):6198\u2013208","journal-title":"Blood"},{"key":"9877_CR7","unstructured":"The US Food and Drug Administration. Drug Approvals and Databases, Mylotarg (gemtuzumab ozogamicin) Injection. [accessed May 30, 2012]; Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21174_Mylotorg.cfm"},{"key":"9877_CR8","unstructured":"The European Medicines Agency. European public assessment reports, Mylotarg. [accessed May 30, 2012]; Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000705\/human_med_000915.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=false"},{"key":"9877_CR9","unstructured":"Pharmaceutical and Medicines Agency. Drug Approvals and Databases, Mylotarg Injection. [accessed May 30, 2012]; Available from: http:\/\/www.info.pmda.go.jp\/shinyaku\/P200500021\/53039600_21700AMY00219_Q100_3.pdf"},{"key":"9877_CR10","unstructured":"The US Food and Drug Administration. Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market. [accessed May 30, 2012]; Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm216448.htm"},{"key":"9877_CR11","unstructured":"Pharmaceutical and Medicines Agency. Assessment report, Mylotarg. [accessed May 30, 2012]; Available from: http:\/\/www.pmda.go.jp\/english\/service\/pdf\/precautions\/PMDSI-277.pdf"},{"issue":"13","key":"9877_CR12","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19(13):3244\u20133254","journal-title":"J Clin Oncol"},{"key":"9877_CR13","first-page":"790","volume":"114","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf S, Kopecky K, Stuart RK et al (2009) Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 114:790","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"9877_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29(4):369\u2013377","journal-title":"J Clin Oncol"},{"key":"9877_CR15","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Tobinai K, Takeshita A et al. Phase I\/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol;89(4):460\u2013469","DOI":"10.1007\/s12185-009-0298-1"},{"key":"9877_CR16","unstructured":"Announcement of the Japanese Society of Medical Oncology. On the Registration System of Mylotarg. [accessed May 30, 2012]; Available from: http:\/\/www.jsmo.or.jp\/news\/jsmo\/20110810.html"},{"key":"9877_CR17","first-page":"6","volume":"118","author":"S Castaigne","year":"2011","unstructured":"Castaigne S, Pautas C, Terre C et al (2011) Fractionated doses of Gemtuzumab Ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50\u201370\u00a0years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). Blood (ASH Annual Meeting Abstracts) 118:6","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"9877_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379:1508\u20131516","journal-title":"Lancet"},{"key":"9877_CR19","first-page":"582","volume":"118","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Hunter A et al (2011) The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood (ASH Annual Meeting Abstracts) 118:582","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"9877_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","volume":"104","author":"F Lo-Coco","year":"2004","unstructured":"Lo-Coco F, Cimino G, Breccia M et al (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104(7):1995\u20131999","journal-title":"Blood"},{"issue":"9","key":"9877_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3324\/haematol.11329","volume":"92","author":"M Breccia","year":"2007","unstructured":"Breccia M, Cimino G, Diverio D et al (2007) Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92(9):1273\u20131274","journal-title":"Haematologica"},{"issue":"32","key":"9877_CR22","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P et al (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 26(32):5192\u20135197","journal-title":"J Clin Oncol"},{"issue":"1","key":"9877_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"AL Taksin","year":"2007","unstructured":"Taksin AL, Legrand O, Raffoux E et al (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 21(1):66\u201371","journal-title":"Leukemia"},{"issue":"11","key":"9877_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B Lowenberg","year":"2011","unstructured":"Lowenberg B, Pabst T, Vellenga E et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364(11):1027\u20131036","journal-title":"N Engl J Med"},{"key":"9877_CR25","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1182\/blood-2010-08-300871","volume":"116","author":"WT Clarke","year":"2010","unstructured":"Clarke WT, Marks PW (2010) Gemtuzumab ozogamicin: is there room for salvage? Blood 116:2618\u20132619","journal-title":"Blood"},{"key":"9877_CR26","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","volume":"102","author":"WJ Kell","year":"2003","unstructured":"Kell WJ, Burnett AK, Chopra R et al (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102:4277\u20134283","journal-title":"Blood"},{"key":"9877_CR27","first-page":"950","volume":"89","author":"S Amadori","year":"2004","unstructured":"Amadori S, Suciu S, Willemze R et al (2004) Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89:950\u2013956","journal-title":"Haematologica"},{"key":"9877_CR28","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA et al (2005) Final report of the efficacy and safety of gemtuzumab onogamicine (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442\u20131452","journal-title":"Cancer"},{"key":"9877_CR29","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"S Amadori","year":"2005","unstructured":"Amadori S, Suciu S, Stasi R et al (2005) Gemtuzumab Ozogamicin (Mylotarg) as single-agent treatment for frail patients 61\u00a0years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Leukemia Groups. Leukemia 19:1768\u20131773","journal-title":"Leukemia"},{"key":"9877_CR30","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","volume":"115","author":"B Lowenberg","year":"2010","unstructured":"Lowenberg B, Beck J, Graux C et al (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60\u00a0years of age or more: results of a multicenter phase 3 study. Blood 115:2586\u20132591","journal-title":"Blood"},{"key":"9877_CR31","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/blood-2010-09-309229","volume":"117","author":"HF Fernandez","year":"2011","unstructured":"Fernandez HF, Sun Z, Litzow MR et al (2011) Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 117:5306\u20135313","journal-title":"Blood"},{"key":"9877_CR32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/annonc\/mdr346","volume":"23","author":"U Brunnberg","year":"2012","unstructured":"Brunnberg U, Mohr M, Noppeney R et al (2012) Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol 23:990\u2013996","journal-title":"Ann Oncol"},{"key":"9877_CR33","unstructured":"Tanimoto T, Kusumi E, Ono S (2012) Regulatory review of novel therapeutics. N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9877-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9877-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:43:00Z","timestamp":1678560180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["9877"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9877-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,11]]},"assertion":[{"value":"25 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}